Journal article
Detection and localization of surgically resectable cancers with a multi-analyte blood test
JD Cohen, L Li, Y Wang, C Thoburn, B Afsari, L Danilova, C Douville, AA Javed, F Wong, A Mattox, RH Hruban, CL Wolfgang, MG Goggins, MD Molin, TL Wang, R Roden, AP Klein, J Ptak, L Dobbyn, J Schaefer Show all
Science | AMER ASSOC ADVANCEMENT SCIENCE | Published : 2018
Abstract
Earlier detection is key to reducing cancer deaths. Here, we describe a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. We applied this test, called CancerSEEK, to 1005 patients with nonmetastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests were positive in a median of 70% of the eight cancer types. The sensitivities ranged from 69 to 98% for the detection of five cancer types (ovary, liver, stomach, pancreas, and esophagus) for which there are no screening tests available for average-risk individuals. The specificity ..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
We thank our patients for their courage and generosity. We are grateful to C. Blair and K. Judge for expert technical and administrative assistance. We thank H. Ren, J. Olson, M. Hathcok, H. Zeh, A. Singhi, S. Crippa, M. Ryan, and L. Ryan for their assistance with this study. This work was supported by the Lustgarten Foundation for Pancreatic Cancer Research; The Virginia and D. K. Ludwig Fund for Cancer Research; The Conrad N. Hilton Foundation; The Commonwealth Fund; The John Templeton Foundation; the Clinomics Program; Mayo Clinic Center for Individualized Medicine; the Mayo Clinic Biobank; The Sol Goldman Center for Pancreatic Cancer Research; The Michael Rolfe Pancreatic Cancer Research Foundation; The Benjamin Baker Scholarship; The Gray Foundation; S. Wojcicki and D. Troper; The Marcus Foundation; The Honorable Tina Brozman Foundation; The Burroughs Wellcome Career Award for Medical Scientists; The Doris Duke Charitable Foundation (2014107); and National Institutes of Health grants P50-CA62924, P50-CA102701, CA06973, CA152753, GM-07309, U01CA200469, and U01CA152753. N.P., S.Z., K.W.K., L.D., and B.V. are founders of Personal Genome Diagnostics and PapGene. B.V. and K.W.K are on the Scientific Advisory Board of SysmexInostics. B.V. is also on the Scientific Advisory Boards of Exelixis GP. R.H.H. is on the Board of Directors of MiDiagnostics. These companies and others have licensed technologies from Johns Hopkins, and N.P., K.W.K., L.D., B.V, and R.H.H. receive equity or royalties from these licenses. The terms of these arrangements are being managed by Johns Hopkins University in accordance with its conflict of interest policies. L.D. is on the Board of Directors of Jounce Therapeutics and is a Scientific Advisor for Genocea, Cell Design Labs, and Merck. A.S.M. is a consultant for Abbvie, Genentech, Bristol-Myers Squibb, and Trovagene. B.V., N.P., and K.W.K. are inventors on a patent (U.S. 20140227705 A1) held by Johns Hopkins University that covers basic aspects of the SafeSeqS technology used in this paper. B.V., K.W.K., N.P., J.D.C., C.T., and A.M.L. are inventors on a patent application to be submitted by Johns Hopkins University that covers other aspects of SafeSeqS as well as the multi-analyte approach described in this paper. All data needed to evaluate the conclusions in the paper are present in the paper and/or the supplementary materials. Contact C.T. for questions about the algorithms; A.M.L. for questions about clinically related issues; K.W.K about the sequencing analyses; B.V. about experimental procedures; and N.P. about the overall design of the study.